



SHAREABLE PDF

Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy

Andrew P. Hearn^{1,2}, Oliver D. Hug², Ziana A. Somani², Joanne Kavanagh^{1,2}, Grainne d'Ancona¹, Cris Roxas¹, Linda Green¹, Louise Thomson¹, Mariana Fernandes¹, Brian D. Kent^{1,3,4}, Jaideep Dhariwal ¹, Alexandra M. Nanzer¹ and David J. Jackson ^{1,2}

Affiliations: ¹Guy's Severe Asthma Centre, Guy's Hospital, Guy's and St Thomas' NHS Trust, London, UK. ²School of Immunology and Microbial Sciences, King's College London, London, UK. ³Dept of Respiratory Medicine, St James' Hospital, Dublin, Ireland. ⁴School of Medicine, Trinity College Dublin, Dublin, Ireland.

Correspondence: David J. Jackson, Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust; School of Immunology and Microbial Sciences, King's College London, SE1 9RT, UK. E-mail: David.Jackson@gstt.nhs.uk

@ERSpublications

In a real-world setting, the clinical response to the anti-IL-5/5R mAbs mepolizumab and benralizumab in patients with severe eosinophilic asthma is independent of co-eligibility with the anti-IgE mAb omalizumab <https://bit.ly/2NfAitP>

Cite this article as: Hearn AP, Hug OD, Somani ZA, *et al.* Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy. *Eur Respir J* 2021; 57: 2100166 [<https://doi.org/10.1183/13993003.00166-2021>].

This single-page version can be shared freely online.

To the Editor:

Mepolizumab and benralizumab are monoclonal antibodies (mAbs) approved for the treatment of severe eosinophilic asthma (SEA), targeting interleukin (IL)-5 and IL-5R, respectively [1]. In appropriately selected patients, their use leads to significant reductions in asthma exacerbations and maintenance oral corticosteroid (mOCS) dose [2, 3].